Ketamine for Chronic Pain: How It Works, Protocols, and Evidence

Chronic pain affects roughly 50 million American adults, and for a significant subset of those people, standard treatments fall short. Opioids lose effectiveness over time and carry well-known risks. Gabapentin and pregabalin help some patients but not others. Physical therapy, nerve blocks, and spinal cord stimulators each have their place but leave many people still searching for relief.

Ketamine entered the chronic pain conversation because it works through a mechanism that none of these standard treatments address. While opioids target opioid receptors and gabapentinoids modulate calcium channels, ketamine blocks NMDA receptors, a key player in a process called central sensitization that drives many chronic pain conditions [1]. This makes ketamine uniquely positioned to treat pain that other medications cannot touch.

This article covers the neuroscience behind ketamine’s pain-relieving effects, the conditions with the strongest evidence, what infusion protocols look like, and what the realistic expectations should be.

How Ketamine Treats Chronic Pain

Understanding why ketamine works for chronic pain requires understanding what goes wrong in the nervous system when pain becomes chronic.

The Central Sensitization Problem

In acute pain, the nervous system functions like an alarm. Tissue damage sends signals through nerve fibers to the spinal cord and brain, where they are processed as pain. When the tissue heals, the alarm turns off.

In chronic pain, the alarm gets stuck. Through a process called central sensitization, neurons in the spinal cord and brain become hypersensitive. They start firing in response to stimuli that should not be painful (allodynia) and overreacting to stimuli that are mildly painful (hyperalgesia). The pain system itself becomes the problem, independent of any ongoing tissue damage [2].

Central sensitization is driven largely by NMDA receptors. When these receptors are chronically activated by sustained pain input, they trigger a molecular cascade that fundamentally changes how pain neurons behave [2]:

• Ion channels become more permeable, making neurons easier to activate
• New receptors are recruited to the cell surface, amplifying the signal
• Gene expression changes in spinal cord neurons, making the sensitization more durable
• Glial cells (support cells in the nervous system) become activated and release inflammatory molecules that further excite pain neurons

This is why chronic pain conditions are so stubbornly resistant to treatment. You are not just dealing with a pain signal. You are dealing with a rewired nervous system.

How NMDA Antagonism Helps

Ketamine blocks NMDA receptors, effectively interrupting the central sensitization cascade at its core [1][3]. This produces several clinically meaningful effects:

• Reduces wind-up. Wind-up is the progressive increase in pain signaling that occurs when NMDA receptors are repeatedly activated. Ketamine stops this cycle.
• Reverses allodynia. By calming hyperexcitable spinal cord neurons, ketamine can reduce or eliminate pain from normally non-painful touch.
• Modulates glial activation. Ketamine reduces the pro-inflammatory signaling from activated glial cells, addressing one of the maintenance factors of chronic pain [3].
• Resets opioid tolerance. NMDA receptor activation is one of the mechanisms behind opioid tolerance (needing higher doses for the same effect). Ketamine can partially reverse this, potentially allowing patients to reduce their opioid doses [4].

Beyond NMDA: Other Mechanisms

Ketamine is not a clean NMDA blocker. It also interacts with opioid receptors (weakly), monoamine transporters (affecting serotonin and norepinephrine levels), and inflammatory pathways [3]. These additional actions likely contribute to its analgesic effects, though NMDA antagonism is considered the primary mechanism.

Ketamine for CRPS: The Strongest Evidence

Complex regional pain syndrome is among the most severe chronic pain conditions known to medicine. It typically develops after an injury (often a limb fracture or surgery) and is characterized by burning pain, swelling, skin changes, and extreme sensitivity to touch, all out of proportion to the original injury. CRPS is considered the poster child for central sensitization.

What the Evidence Shows

A consensus guideline published in Regional Anesthesia and Pain Medicine reviewed the evidence for ketamine infusions across all chronic pain conditions and found the strongest support for CRPS [1].

Key findings from the CRPS literature:

• Outpatient low-dose infusions (0.5 mg/kg over 4 hours): A randomized, double-blind, placebo-controlled trial by Sigtermans and colleagues found that a series of ketamine infusions produced significant pain relief in CRPS patients compared to placebo, with effects lasting a median of 11 weeks after treatment [5].
• Multi-day inpatient infusions: Higher-dose protocols (up to 0.35 mg/kg/hour over 4 to 5 days) have shown response rates of 50 to 80% in open-label studies, with some patients achieving remission lasting months [6].
• Subanesthetic “ketamine coma” protocols: Performed in specialized centers (primarily outside the United States), these involve very high doses administered under general anesthesia for 5 to 7 days. Case series report dramatic responses, including complete remission in some patients, though the risks and costs are substantial [7].

Duration of Relief

The duration of ketamine’s pain-relieving effects in CRPS varies widely:

• After a single outpatient infusion: 2 to 4 weeks of benefit
• After a series of 4 to 6 outpatient infusions: 4 to 12 weeks
• After multi-day inpatient protocols: Weeks to months, with some reports of years

Most CRPS patients need periodic retreatment, but the interval between treatments often increases over time as the central sensitization gradually resets.

Ketamine for Fibromyalgia

Fibromyalgia is a widespread pain condition increasingly understood as a disorder of central pain processing. Central sensitization plays a major role, which makes ketamine a logical candidate.

What the Research Shows

A double-blind, randomized controlled trial by Noppers and colleagues tested a single IV ketamine infusion (0.5 mg/kg over 30 minutes) in fibromyalgia patients [8]. The results were mixed: ketamine produced significant short-term pain reduction compared to placebo, but the effects were relatively brief (lasting about 1 week).

A longer infusion protocol (multiple sessions over 2 to 3 weeks) has shown more promising results in open-label studies, with patients reporting sustained improvements in pain, fatigue, and quality of life for several weeks after the treatment series [9].

Clinical Reality

The evidence for ketamine in fibromyalgia is moderate. It is not a first-line treatment, and most pain specialists consider it an option for patients who have failed standard fibromyalgia therapies (duloxetine, pregabalin, exercise programs, cognitive behavioral therapy). When it works, patients often describe it as a significant reset of their pain levels, though maintenance infusions are typically needed.

Pain Condition	Evidence Strength	Typical Response Rate	Duration of Benefit
CRPS	Strong	50 to 80%	Weeks to months
Neuropathic pain	Moderate	30 to 60%	2 to 6 weeks per infusion
Fibromyalgia	Moderate	30 to 50%	1 to 4 weeks per infusion
Phantom limb pain	Limited	Variable	Variable
Refractory migraine	Emerging	40 to 60% (case series)	Days to weeks
Spinal cord injury pain	Limited	Variable	Variable

Ketamine for Neuropathic Pain

Neuropathic pain results from damage or dysfunction in the nervous system itself, whether from diabetic neuropathy, postherpetic neuralgia, nerve injuries, or conditions like small fiber neuropathy. NMDA receptors play a central role in maintaining neuropathic pain states, making ketamine a mechanistically appropriate treatment [10].

The Evidence

A Cochrane systematic review examined ketamine for neuropathic pain and found evidence of short-term analgesic benefit, though the quality of available studies was generally low and the optimal dosing protocols remained unclear [10]. More recent studies have focused on infusion series rather than single doses, with better results.

A practical observation from pain clinics: patients with burning, electric, or shooting pain (characteristics of neuropathic pain with strong central sensitization) tend to respond better to ketamine than patients with primarily mechanical or movement-related pain.

Specific Neuropathic Conditions

Postherpetic neuralgia: Small studies suggest ketamine infusions can reduce pain in patients with shingles-related nerve pain that has not responded to gabapentin, pregabalin, or topical lidocaine.Diabetic neuropathy: Limited evidence but biological rationale is strong, as NMDA receptor activation is implicated in diabetic neuropathic pain mechanisms.Chemotherapy-induced neuropathy: Preliminary data suggests potential benefit, though this is an area where more research is needed.

Infusion Protocols for Pain

Ketamine infusion protocols for chronic pain differ from the protocols used for depression. Pain protocols are more variable, sometimes higher dose, and often administered over longer durations.

Outpatient Low-Dose Protocol

• Dose: 0.5 to 1.0 mg/kg administered IV over 1 to 4 hours
• Frequency: 3 to 6 infusions over 2 to 3 weeks
• Setting: Outpatient clinic with vital sign monitoring
• Duration of appointment: 2 to 5 hours (including monitoring after infusion)
• What to expect: Dissociation, mild dizziness, nausea (usually manageable), temporary blood pressure elevation

This is the most common protocol and the one most patients start with. The goal is to gradually reset central sensitization through repeated treatments.

Multi-Day Inpatient Protocol (for CRPS and Severe Cases)

• Dose: Higher continuous infusion (0.1 to 0.35 mg/kg/hour) over 4 to 7 days
• Setting: Hospital or specialized pain center with continuous monitoring
• Cost: $5,000 to $15,000+ depending on duration and facility
• Candidates: Patients with severe CRPS or refractory neuropathic pain who have not responded to outpatient protocols

These protocols carry higher risk due to the longer duration and higher cumulative dose. Blood pressure, heart rate, and liver function are monitored throughout. Patients may experience more pronounced dissociation and require anti-nausea medication.

Maintenance and Booster Infusions

After an initial treatment series, most chronic pain patients need periodic booster infusions. The interval varies:

• Some patients do well with monthly infusions
• Others can stretch to every 2 to 3 months
• A subset of patients with milder central sensitization achieve lasting benefit after a single course

The goal of maintenance therapy is to extend the interval between infusions over time as the nervous system gradually “unlearns” its sensitized state.

At-Home Ketamine Options for Pain

The growth of telehealth ketamine services has made at-home treatment more accessible. These programs typically prescribe sublingual ketamine lozenges (troches) or rapid-dissolving tablets that patients self-administer under remote medical supervision.

How At-Home Protocols Work

• A physician evaluates you via telehealth and prescribes sublingual ketamine (typical dose: 100 to 400 mg per session)
• You receive the medication from a compounding pharmacy
• You take the lozenge at home, usually lying down in a comfortable environment with a monitor or guide available by phone/video
• Sessions typically last 1 to 2 hours

Pros and Cons

Advantages: Lower cost ($150 to $350 per month vs. $400 to $800 per IV infusion), no travel to a clinic, greater flexibility in scheduling.Limitations: Lower bioavailability than IV (roughly 25 to 30% absorption through the mucous membranes vs. nearly 100% IV). More variable dosing. Less medical supervision during the experience. Some chronic pain conditions that respond well to IV ketamine may not respond to sublingual dosing because the blood levels achieved are lower.

When At-Home Makes Sense

At-home ketamine is reasonable for patients with chronic pain who:

• Have already responded positively to IV ketamine and are transitioning to a maintenance strategy
• Cannot afford or access regular IV infusions
• Have milder pain conditions where lower doses may be sufficient
• Are also managing co-occurring depression or anxiety (where sublingual dosing has more evidence)

It is generally not recommended as a first-line approach for severe pain conditions like CRPS, where higher, precisely controlled doses are needed.

Who Is a Good Candidate?

Ketamine for chronic pain is generally considered when:

• You have a pain condition with a strong central sensitization component (CRPS, neuropathic pain, fibromyalgia)
• You have tried and failed standard treatments (medications, nerve blocks, physical therapy)
• Your pain significantly impairs your quality of life and function
• You do not have contraindications (uncontrolled hypertension, active psychosis, history of ketamine abuse)

Ketamine is less likely to help if:

• Your pain is primarily mechanical or structural (e.g., bone-on-bone arthritis, acute disc herniation)
• You are seeking a permanent cure (ketamine manages central sensitization but does not eliminate the underlying condition)
• You have active substance use disorders that have not been addressed

Cost Considerations

Ketamine for chronic pain is rarely covered by insurance when administered as an off-label infusion. Typical out-of-pocket costs:

• Single outpatient infusion: $400 to $800
• Initial course of 6 infusions: $2,400 to $4,800
• Multi-day inpatient protocol: $5,000 to $15,000+
• Monthly maintenance infusion: $400 to $800
• At-home sublingual program: $150 to $350 per month

Some patients find that the reduction in other pain medications, fewer ER visits, and improved ability to work offsets a significant portion of the ketamine cost. This is a conversation worth having with your provider when evaluating the financial picture.

When to See a Doctor

Discuss ketamine therapy with a pain management specialist if:

• You have CRPS, neuropathic pain, or fibromyalgia that has not responded to standard treatments
• Your current pain medications are losing effectiveness or causing intolerable side effects
• You are on chronic opioids and want to explore options for reducing your dose
• You have heard about ketamine and want a professional assessment of whether it is appropriate for your condition

For a broader overview of ketamine therapy, including its use for depression and PTSD, see our ketamine therapy guide. For information about how ketamine compares to other pain management approaches, our chronic pain guide provides a wider perspective.

The Bottom Line

Ketamine treats chronic pain through a mechanism that no other widely available analgesic addresses: NMDA receptor blockade and reversal of central sensitization. The evidence is strongest for CRPS, where response rates of 50 to 80% have been documented in published studies. For neuropathic pain and fibromyalgia, the evidence is moderate but growing. For other chronic pain conditions, the data is earlier-stage.

Ketamine is not a first-line pain treatment, and it is not a permanent cure. It is a powerful tool for patients who have exhausted standard options and whose pain involves a significant central sensitization component. When used in the right context, by the right provider, with realistic expectations, ketamine can provide meaningful relief for people who thought they had run out of options.

Related Reading

• Ketamine Therapy: The Complete Guide
• Chronic Pain Management Guide
• Small Fiber Neuropathy Symptoms

References

[1] Cohen SP, Bhatia A, Buvanendran A, et al. Consensus guidelines on the use of intravenous ketamine infusions for chronic pain from the American Society of Regional Anesthesia and Pain Medicine. Reg Anesth Pain Med. 2018;43(5):521-546. PMID: 29870458

[2] Latremoliere A, Woolf CJ. Central sensitization: a generator of pain hypersensitivity by central neural plasticity. J Pain. 2009;10(9):895-926. PMID: 19712899

[3] Niesters M, Martini C, Dahan A. Ketamine for chronic pain: risks and benefits. Br J Clin Pharmacol. 2014;77(2):357-367. PMID: 23432384

[4] Laulin JP, Maurette P, Corcuff JB, Rivat C, Chauvin M, Simonnet G. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94(5):1263-1269. PMID: 11973202

[5] Sigtermans MJ, van Hilten JJ, Bauer MC, et al. Ketamine produces effective and long-term pain relief in patients with complex regional pain syndrome type 1. Pain. 2009;145(3):304-311. PMID: 19604642

[6] Schwartzman RJ, Alexander GM, Grothusen JR, Paylor T, Reichenberger E, Perreault M. Outpatient intravenous ketamine for the treatment of complex regional pain syndrome: a double-blind placebo controlled study. Pain. 2009;147(1-3):107-115. PMID: 19783371

[7] Kiefer RT, Rohr P, Ploppa A, et al. Efficacy of ketamine in anesthetic dosage for the treatment of refractory complex regional pain syndrome: an open-label phase II study. Pain Med. 2008;9(8):1173-1201. PMID: 18266808

[8] Noppers I, Niesters M, Swartjes M, et al. Absence of long-term analgesic effect from a short-term S-ketamine infusion on fibromyalgia pain: a randomized, prospective, double blind, active placebo-controlled trial. Eur J Pain. 2011;15(9):942-949. PMID: 21482474

[9] Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, et al. Ketamine reduces muscle pain, temporal summation, and referred pain in fibromyalgia patients. Pain. 2000;85(3):483-491. PMID: 10781923

[10] Amr YM. Multi-day low dose ketamine infusion as adjuvant to oral gabapentin in spinal cord injury related chronic pain: a prospective, randomized, double blind trial. Pain Physician. 2010;13(3):245-249. PMID: 20495588